Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics to Offer High-Throughput Antibody Production

NEW YORK, March 1 (GenomeWeb News) - Strategic Diagnostics said today that it will offer a new high-throughput antibody reagent production service for customers in the proteomics, pharmaceutical, diagnostics, and biomedical research industries.

 

The technology, based on a process called genetic immunization, will allow Strategic Diagnostics to manufacture custom antibodies in high throughput based on specific genetic sequences provided by the customer, the company said.

 

Strategic Diagnostics, which is based in Newark, Del., also said that it has opened a research facility in Dallas dedicated to the new service, and has hired two new scientists to oversee the initiative: Ross Chambers and David Fancy, who join the company from the University of Texas, Southwestern Medical Center. Chambers and Fancy are widely recognized for their work in genetic immunization, Strategic Diagnostics said.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.